Protein Arginine Methyltransferase 1 (PRMT1) Selective Inhibitor, TC-E 5003, Has Anti-Inflammatory Properties in TLR4 Signaling
Protein arginine methyltransferase 1 (PRMT1) is the most predominant PRMT and is type I, meaning it generates monomethylarginine and asymmetric dimethylarginine. PRMT1 has functions in oxidative stress, inflammation and cancers, and modulates diverse diseases; consequently, numerous trials to develo...
Main Authors: | Eunji Kim, Jiwon Jang, Jae Gwang Park, Kyung-Hee Kim, Keejung Yoon, Byong Chul Yoo, Jae Youl Cho |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/9/3058 |
Similar Items
-
Developing protein arginine methyltransferase 1 (PRMT1) inhibitor TC-E-5003 as an antitumor drug using INEI drug delivery systems
by: Pengcheng Zhang, et al.
Published: (2020-01-01) -
Arginine Methyltransferase PRMT1 Regulates p53 Activity in Breast Cancer
by: Li-Ming Liu, et al.
Published: (2021-08-01) -
The protein arginine methyltransferase PRMT1 promotes TBK1 activation through asymmetric arginine methylation
by: Zhenzhen Yan, et al.
Published: (2021-09-01) -
The Role of Protein Arginine Methyltransferases in DNA Damage Response
by: Charles Brobbey, et al.
Published: (2022-08-01) -
Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review
by: Kavanya Feustel, et al.
Published: (2022-08-01)